• Health
  • Science
  • U.S.
  • Technology
  • Business
  • World
  • Politics
  • Entertainment
  • Sports

Building a Better World

News and information

  • Home
  • Privacy Policy
  • Contact Us
  • Our Team

This major drug company is in huge trouble

December 26, 2015 By Sam Catherman

This major drug company is in huge trouble

Tough times may be ahead for Valeant Pharmaceuticals, a leading drug company based in Laval, Quebec.

When the CEO of Valeant Pharmaceuticals International Inc. fell ill with pneumonia, panic began to spread throughout the company. Now, according to a report from Bloomberg, the chief executive’s current status is unknown and the company’s stock plummeted 57 percent from its high point due to a number of scandals.

J. Michael Pearson, aged 56, was admitted to the hospital on Christmas. A spokeswoman from the company, Laurie Little, revealed on Friday that the CEO was admitted and treated, but declined to provide more details about the boss’s illness. “We wish him a speedy recovery and look forward to him returning to work when he is feeling better,” Little said. “We will be respecting Mike and his family’s privacy during this time and will provide further details on his condition as appropriate.”

The company’s stock has dropped 57 percent from its high point in August, but Pearson remained optimistic as he spoke to investors about new products with high growth potential last week. He promised shareholders that data would be more transparent moving forward, but reports of the meeting revealed that the CEO’s tone was defiant and unapologetic about the company’s long term strategies.

Valeant has drawn criticism in recent months from legislators and shareholders for using mail-order pharmacies, increasing prices, and acquiring a number of businesses with the hopes of growing.

Pearson’s recent deal with Walgreens Boots Alliance Inc. to sell Valeant’s products in their pharmacies at a discount represents the company’s efforts to demonstrate sound practices to their investors, but the company’s stock paints a different picture altogether.

While Pearson is expected to make a full recovery, it remains unclear whether or not investors will regain confidence Valeant.  

A press release from Valeant describing their current financial situation can be found here.

 

Sharing

Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Filed Under: Business, Front Page

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Follow Us

Facebookrss

Search:

Recent Posts

  • NASA’s InSight spacecraft makes important course correction May 26, 2018
  • Scientists outraged at latest Trump decision May 15, 2018
  • Huge uproar erupts over major incident at Utah park May 13, 2018
  • Incredible moon discovery stuns scientists May 12, 2018
  • Authorities shocked by discovery about common painkiller May 6, 2018
  • Outrageous crocodile experiment stuns scientists May 5, 2018
  • Great Barrier Reef is too quiet, scientists say May 1, 2018
  • Massive Hiroshima bomb discovery shocks scientists May 1, 2018
  • Earth will be slammed by massive asteroid April 29, 2018
  • Teens are doing something incredibly alarming in schools April 29, 2018
  • Huge discovery in Tasmania stuns scientists April 28, 2018
  • Shocking discovery in New Jersey stuns authorities April 22, 2018
  • Huge volcanic explosion could wipe out the United States April 21, 2018
  • Huge controversy erupts over world’s hottest pepper April 15, 2018
  • SpaceX is about to do something astonishing April 15, 2018

Copyright © 2019 Jones Kilmartin Group, LLC · Metro Pro Theme On Genesis Framework · WordPress